ArticleMaterials today. Bio2025
Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells via injectable microfluidic-templated microgels for retinal regeneration.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Injectable alginate hydrogels improve the effects of subretinal hiPSC-derived RPE cell therapy on retinal degeneration in rats.Materials today. Bio · 2026Article
- Ultrasound-Responsive Microcapsules Delivering Oxygen and Traditional Chinese Medicine for Wound Healing.Smart medicine · 2025Article
- Retinal Pigment Epithelium Transplantation in Retinal Disease: Clinical Trial Development, Challenges, and Future Directions.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinal pigment epithelial (RPE) cells are specialized neural cells crucial for vision, while human embryonic stem cell-derived retinal pigment epithelial (hESC-RPE) cells hold great potential as a viable cell source for treating retinal degenerative diseases like retinitis pigmentosa (RP). However, the transplantation efficiency and viability of hESC-RPE cell suspensions are relatively low due to detrimental shear-force during operations and host immune-clearance. We herein develop an alternative transplantation strategy with the aid of a microfluidic-templating microgel cell carrier to achieve substantially enhanced loading and delivery efficiency of hESC-RPE cells, thereby promoting visual function recovery after subretinal injection in the RP model Royal College of Surgeons (RCS) rats. Specifically, injectable monodispersed microgels consisting of gelatin-methacryloyl/Hyaluronic acid-methacryloyl core coated with fibrin shell (denoted as Fib@GHMS) were fabricated in a high-throughput and controllable manner, facilitating the adhesion and proliferation of hESC-RPE cells. RCS rats treated with microcarriers showed significantly improved visual function, evidenced by increased B-wave amplitudes and the preservation of the inner nuclear layer at 8 weeks post-surgery. In conclusion, our innovative delivery system Fib@GHMS for hESC-RPE cell transplantation presents a potential therapeutic graft for retinal tissue engineering. It may open a new avenue for clinical transplantation of minimally invasive cell-based treatments in retinal degenerative diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.